Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. (JAGX) on March 8, 2024, covering events occurring on March 1, 2024, and March 5, 2024. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The report focuses exclusively on a specific capital transaction.
Material Changes
The primary material event reported is the unregistered sale of equity securities via a privately negotiated exchange agreement with Streeterville Capital, LLC:
- March 1, 2024: The Company issued 179.3822 shares of Series J Preferred Stock to Streeterville.
- March 5, 2024: The Company issued 10,000,000 shares of common stock in exchange for the surrender and cancellation of 40 shares of Series J Perpetual Preferred Stock held by Streeterville.
- Regulatory Basis: The common stock issuance relied on the exemption from registration under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the standard disclosure of the equity exchange transaction.
Investor Verification Checklist
- Verify the impact of the 10,000,000 new common shares on total outstanding share count and potential dilution.
- Review the terms of the Series J Preferred Stock to understand the conversion mechanics and rights surrendered.
- Confirm the identity and relationship of Streeterville Capital, LLC with the Company.
- Check subsequent filings for any updated capitalization tables reflecting this transaction.